Genevention

Genevention is a bioinformatics company based in Göttingen, Germany. It describes itself as bringing together long-standing experience in the semantic integration of biomedical big data, cutting-edge deep data analyses and sharp visualizations for interactive data exploration. Its stated aim is to combine these technologies so that biomedical researchers, pharmaceutical engineers and bioinformaticians can discover disease-specific biomarkers, reveal novel correlations in datasets across different experiment types, and easily enrich experimental data with information from the literature and external databases. The company's commercial offering is built around software and expert services. Its flagship product is Semares, a software platform for managing and analyzing omics data, with advanced features for semantic biomedical data integration, workflow analysis and visualization. Semares includes a single-cell transcriptomics module that lets users integrate, analyze and visualize gene expression data, uncover differences between clusters, and connect single-cell profiles to bulk data. Alongside the software, Genevention provides customized semantic data integration solutions built on the Semares platform and a broad range of bioinformatics analytics services, including study design support, data identification and organization, data quality control, and the application of machine learning techniques. Genevention also works on applied research and development projects. Its website highlights the AMBROSIA project, in which the company develops a data integration platform and machine learning tools for the prediction of undernutrition and treatment outcome assessment in elderly people, particularly in older people with heart failure and atrial fibrillation. The company publishes scientific research, including work on neurobehavioral signatures of stress resilience in mice and on non-destructive surveillance of osteogenic differentiation potential in cell cultures. Leadership listed on the company's About Us page includes Dr. Thomas Lingner as CEO, described as a data scientist with a strong background in computational biology whose expertise covers data mining and machine learning, high-throughput sequence analysis and metagenomics. Prof. Dr. Stefan Bonn, a biochemist and computational biologist with a background in deep learning and data analysis, and Dr. Herbert Stadler, a neuroscientist and biotech entrepreneur, are listed as co-founders and members of the advisory board. The company is headquartered in Göttingen, Germany, and serves partners from both academia and industry.

Genevention is a bioinformatics company located in Göttingen, Germany. Public information about the company is concentrated in its own website and a Wikidata entry describing it as a company in Göttingen, Germany. The company presents itself as combining long-standing experience in the semantic integration of biomedical big data, cutting-edge deep data analyses and sharp visualizations for interactive data exploration. From its founding, the company has been associated with a leadership group drawn from computational biology, biochemistry and biotechnology entrepreneurship. Dr. Thomas Lingner serves as CEO and is described as a data scientist with a strong background in computational biology, covering data mining and machine learning, high-throughput sequence analysis and metagenomics. Prof. Dr. Stefan Bonn, a biochemist and computational biologist with a background in deep learning and data analysis, and Dr. Herbert Stadler, a neuroscientist and biotech entrepreneur, are listed as co-founders and advisory board members. The company's product line centers on Semares, a software product designed to help manage and analyze omics data while providing advanced features for semantic biomedical data integration, workflow analysis and visualization. Genevention positions Semares as a complete solution for scientists and researchers in the life sciences industry, addressing the challenge of managing the large and growing volumes of data generated by high-throughput sequencing technologies. A single-cell transcriptomics module extends the platform to the integration, analysis and visualization of gene expression data, allowing users to uncover differences between clusters and connect single-cell profiles to bulk data. Beyond software, Genevention offers customized semantic data integration solutions based on the Semares platform and a broad range of bioinformatics analytics services. The company emphasizes the crucial steps of getting the data and getting the data analyzed appropriately, including comprehensive data quality controls, identification of suitable databases, verification that datasets are qualified for planned analyses, study design, data organization and the application of cutting-edge machine learning techniques. It reports successful projects with different partners from academia and industry. Genevention also engages in applied research and development. Its website highlights the AMBROSIA project, in which the company develops a data integration platform and machine learning tools for the prediction of undernutrition and treatment outcome assessment in elderly people, particularly older people with heart failure and atrial fibrillation, where undernutrition is described as a key factor leading to inflammation, loss of function, disability and ultimately death. The company also lists scientific publications, including work on fear circuit-based neurobehavioral signatures mirroring resilience to chronic social stress in mice, on 99mTc-HDP labeling as a non-destructive method for real-time surveillance of osteogenic differentiation potential of hMSC during ongoing cell cultures, and on enabling technologies towards personalization of scaffolds for large bone defect regeneration. The company is headquartered in Göttingen, Germany, and serves partners from academia and industry. It is a private company; no public listing, parent company or ownership structure is indicated in the available evidence.

• Genevention is established as a bioinformatics company in Göttingen, Germany.

• Semares is developed as a software product for omics data management, semantic biomedical data integration, workflow analysis and visualization.

• A single-cell transcriptomics module is added to Semares for integration, analysis and visualization of gene expression data.

• Genevention develops a data integration platform and machine learning tools for prediction of undernutrition and treatment outcome assessment in elderly people (AMBROSIA).

Bioinformatics software and services provider combining semantic big-data integration, AI-driven analysis and interactive visualization for life-sciences research and industry.

• Semares

  Software product designed to help manage and analyze omics data, with advanced features for semantic biomedical data integration, workflow analysis and visualization.

• Semares single-cell transcriptomics module

  Module that lets users integrate, analyze and visualize gene expression data, uncover differences between clusters, and connect single-cell profiles to bulk data.

• Custom semantic data integration solutions

  Customized semantic data integration solutions based on the Semares platform.

• Bioinformatics analytics services

  Data management and computational analysis solutions for a broad range of life science research projects, including study design, data organization and machine learning.

• Biomarker knowledge bases

  Expert-curated biomarker knowledge bases based on high-throughput-omics data.

1. 1Genevention – official website homepagegenevention.com
2. 2Genevention – Productsgenevention.com
3. 3Genevention – Servicesgenevention.com
4. 4Genevention – About Usgenevention.com
5. 5Wikidata – Genevention (Germany)wikidata.org